New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
AnaptysBio, Inc.
ANAB
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

1B

Biotechnology

Next Earning date - 07 Nov 2024

1B

Biotechnology

Next Earning date - 07 Nov 2024

34.02USD
Shape-1.13 ( -3.21%)
Market Open
favorite-chart

Relative Strenght

43
favorite-chart

Volume Buzz

-76%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

18%

Quote Panel

Shape
Updated October 23, 2024
1W -2.91 % 1M -2.08 % 3M -7.44 % 1Y 93.51 %

Key Metrics

Shape
  • Market Cap

    1.03B


  • Shares Outstanding

    30.20M


  • Share in Float

    25.82M


  • Dividende

    0


  • Earning Date

    07 Nov 2024


  • Price Target

    34.02


  • Average Volume

    302473


  • Beta

    -0.287


  • Range

    13.36-41.308


  • Industry

    Biotechnology


  • Website

    https://www.anaptysbio.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

34.83x

P/S Ratio

97.33x

P/B Ratio

36.8

Debt/Equity

-558.2%

Net Margin

$-6.3

EPS

How ANAB compares to sector?

P/E Ratio

Relative Strength

Shape

ANAB

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$32M

Shape189%

2025-Revenue

$6.69

Shape-291%

2025-EPS

$26M

Shape34%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Wedbush

upgrade

Previous: Neutral

2024-03-12

Now: Outperform

Raymond James

downgrade

Previous: Outperform

2023-01-06

Now: Market Perform

Craig-Hallum

downgrade

Previous: Not converted

2022-11-01

Now: Hold

Wells Fargo

downgrade

Previous: Not converted

2022-11-01

Now: Underweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-1.18
vs -0.24

Q4.22

arrow
arrow

N/A

-0.93
vs -1.13

Q1.23

arrow
arrow

N/A

-1.58
vs -1.31

Q2.23

arrow
arrow

N/A

-1.50
vs -1.15

Q3.23

arrow
arrow

N/A

-1.41
vs -1.18

Q4.23

arrow
arrow

N/A

-1.59
vs -0.93

Q1.24

arrow
arrow

N/A

-1.64
vs -1.58

Q2.24

arrow
arrow

N/A

-1.71
vs -1.50

Q3.24

arrow
arrow

N/A

-1.70
vs -1.41

Q4.24

arrow
arrow

N/A

-1.66
vs -1.59

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-94%

1.3M  vs 20.9M

Q4.22

arrow
arrow

+573%

6.8M  vs 1M

Q1.23

arrow
arrow

+42%

1.4M  vs 970K

Q2.23

arrow
arrow

+185%

3.5M  vs 1.2M

Q3.23

arrow
arrow

+157%

3.3M  vs 1.3M

Q4.23

arrow
arrow

+32%

9M  vs 6.8M

Q1.24

arrow
arrow

+422%

7.2M  vs 1.4M

Q2.24

arrow
arrow

+217%

11M  vs 3.5M

Q3.24

arrow
arrow

+109%

6.9M  vs 3.3M

Q4.24

arrow
arrow

-22%

7M  vs 9M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-13%

-0.13
vs -0.12

Q4.22

arrow
arrow

-10%

-0.10
vs -0.13

Q1.23

arrow
arrow

-25%

-0.25
vs -0.10

Q2.23

arrow
arrow

-27%

-0.27
vs -0.25

Q3.23

arrow
arrow

-31%

-0.31
vs -0.27

Q4.23

arrow
arrow

-48%

-0.48
vs -0.31

Q1.24

arrow
arrow

-92%

-0.92
vs -0.48

Q2.24

arrow
arrow

-472%

-4.72
vs -0.92

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

114

114
vs 125

-9%

Q4.22

arrow
arrow

120

120
vs 114

5%

Q1.23

arrow
arrow

118

118
vs 120

-2%

Q2.23

arrow
arrow

123

123
vs 118

4%

Q3.23

arrow
arrow

122

122
vs 123

-1%

Q4.23

arrow
arrow

124

124
vs 122

2%

Q1.24

arrow
arrow

138

138
vs 124

11%

Q2.24

arrow
arrow

136

136
vs 138

-1%

Earnings Growth

Latest News